Dr. Sabrina Paganoni, Massachusetts General Hospital, will discuss CENTAUR, a trial for people with ALS. CENTAUR ("Combination of Phenylbutyrate and Tauroursodeoxycholic Acid") is a Phase 2 trial testing the efficacy and safety of AMX0035 for the treatment of ALS as well as its impact on several disease biomarkers. CENTAUR is expected to enroll 132 participants nationwide.
In partnership with The ALS Association, NEALS offers live webinars for people with ALS, caregivers and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. Our webinars also offer participants the opportunity to ask questions directly of the experts running clinical trials and conducting research activities.
Presenter: John M. Costello, MA, CCC-SLP, ALS Augmentative Communication Program, Boston Children's Hospital
This webinar will focus on a variety of communication supports that a person with ALS may consider including early simple speech and writing strategies, creating and learning simple quick access tools, message and voice banking and examples of sophisticated technologies that are currently available to support communication, email, texting, telephone and environmental controls.
Anne-Marie Wills, MD, MPH, Massachusetts General Hospital, will present the results of the EAT MORE (E-health Application To Monitor Outcomes Remotely) study and Jane Hubbard, MS, RD, LDN, Massachusetts General Hospital, will review nutrition recommendations and tips for patients with ALS.